Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2004

View Archived Issues

TT-232, a somatostatin analogue, demonstrates in vivo antitumor activity

Novel DNA intercalating agent for antitumor therapy described

Allergan plans IND filing for Peplin's topical drug for actinic keratosis

Nanogen to acquire SYN X Pharma

Lundbeck and Merck & Co. to develop and commercialize gaboxadol

Chiesi and 3M to develop Modulite HFA products for North America

MediGene completes enrollment in final phase III trial of Polyphenon E

Eisai reports on progress of global clinical development

Maxim reviews first quarter developments

Praecis achieves primary goal for 2003

Efficacy and safety of efalizumab in the treatment of psoriasis

Improved epithelial chloride transport found with Moli-1901 in cystic fibrosis

Pregabalin reported effective and safe as adjunctive therapy for patients with partial seizures

Hyperleptinemia in lean ZDF rats reduces weight and converts white adipocytes into fat burning cells

Poseidon claims new BK(Ca) channel modulators for respiratory and cardiovascular disorders

New factor Xa/factor VIIa inhibitors covered by Merck KGaA patent

Novel caspase inhibitors discovered by Vertex researchers

New NPY Y5 antagonists and their use reported by Banyu

Pharmacia team prepares and tests new MMP inhibitors

Aventis describes adenosine A1 agonists with potential as antidiabetic agents

New beta3-adrenoceptor agonists and their use in urinary incontinence

Myfortic completes European mutual recognition procedure

Riomet launched in U.S.

New phase II trial studies effects of ALT-711 on endothelial function

Improvement in cognitive function in schizophrenics after switch to ziprasidone

Aeroneb Go Nebulizer available in U.S.

Orphan drug status for Altastaph

IND filing for phase I/II AVENGE trial of EW-A-401

Fast track status for Fibrillex

Third of four phase II trials initiated for PI-88

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...